AstraZeneca (AZN) Q2 2026 earnings review
Oncology Powers Through the Farxiga Patent Cliff
AstraZeneca's Q2 2026 results confirm management's prior warnings: 2026 is a transition year. Total Revenue grew a stable 6% year-over-year to $15.38 billion, masking a massive internal shift. The Cardiovascular, Renal & Metabolism (CVRM) segment reversed into a steep decline due to the anticipated Farxiga loss of exclusivity in the U.S. and pricing pressures in China. Fortunately, robust double-digit growth in Oncology and tight cost controls allowed Core EPS to surge 21% to $2.63. Management maintained their full-year guidance, demonstrating confidence that their diversified pipeline can absorb the generic hit without derailing their path to $80 billion by 2030.
🐂 Bull Case
The Oncology segment continues to accelerate, growing 16% in Q2. Blockbusters like Enhertu (+33%) and Tagrisso (+13%) are more than making up for shortfalls elsewhere.
Despite top-line headwinds from generics, Core Operating Margin expanded by 2 percentage points to 34%. Core EPS growth (+21%) significantly outpaced revenue growth (+6%), proving the business model scales highly efficiently.
🐻 Bear Case
Farxiga revenue collapsed 16% YoY. Total CVRM revenue shrank 15%, proving the U.S. generic entry and China Volume-Based Procurement (VBP) are biting as hard as feared.
Total revenue in China reversed to a 7% decline. While management historically cited China as a growth engine, regulatory pricing mechanisms (VBP) are actively destroying value in the region.
⚖️ Verdict: 🟢
Bullish. The CVRM cliff was widely telegraphed and completely expected. The fact that AstraZeneca can absorb a 16% drop in one of its largest drugs while still expanding margins and growing overall revenue by 6% is a testament to pipeline breadth.
Key Themes
Oncology Franchise Remains the Ultimate Growth Engine
Oncology growth remains stable and robust at 16% YoY, reaching $7.33 billion in Q2. Enhertu continues to be a standout, accelerating 33% YoY to $888 million on the back of new HER2-low and pan-tumor approvals. Imfinzi (+12%) and Tagrisso (+13%) also displayed exceptional strength, fueled by expansion into earlier lines of therapy. This segment is single-handedly carrying the company's top line.
The Farxiga Cliff Arrives
The long-awaited generic hit to Farxiga is materializing rapidly. Sales are reversing aggressively, falling 16% YoY globally in Q2 to $1.8 billion. This caused the entire CVRM segment to decline 15%. This drag will persist for the next several quarters until base effects normalize.
Operating Leverage is Delivering EPS Beats
AstraZeneca's profitability profile is accelerating. Core Operating Margin reached 34%, up 200 basis points from last year. Core SG&A expenses grew just 7%, tightly matching revenue growth, while Core R&D stayed disciplined at 24% of Total Revenue. This excellent cost control drove a 21% jump in Core EPS despite sluggish top-line dynamics.
Rare Disease Growth Decelerates, Contradicting the 'Pillar' Narrative
Management previously touted the Alexion/Rare Disease portfolio as a highly reliable double-digit growth engine (+15% YoY in Q1 2026). However, Q2 tells a decelerating story: segment growth slowed to just 9%. This was driven by a massive 27% collapse in legacy Soliris revenues, which the 9% growth in Ultomiris failed to offset at the historical rate. The transition to the newer drug is cannibalizing the base faster than expected.
Respiratory & Immunology Steps Up
The R&I segment is showing stable double-digit growth, acting as a crucial secondary offset to CVRM losses. R&I grew 13% in Q2, driven by Tezspire's massive 46% surge to $390 million and steady Fasenra uptake (+14%). The new launch of Airsupra (+19% sequential demand) adds a long-term growth tail.
China Macro Pressures Bite Hard
Total revenue in China reversed into negative territory, shrinking 7% YoY (13% at CER) to $1.59 billion in Q2. Management attributes this to Volume-Based Procurement (VBP) policies impacting key legacy drugs. This highlights a persistent macro-regulatory headwind in what was once a highly reliable emerging market.
Strategic Pipeline In-Licensing
In a bid to plug future revenue gaps, AstraZeneca spent aggressively in July 2026 on two major regional deals: acquiring global rights to Dizal's Zegfrovy (novel EGFR inhibitor) for $600 million upfront, and an exclusive license for Sino Biopharma's TQC3721 (PDE3/4 inhibitor) for $200 million upfront. This shows a continued focus on acquiring de-risked, clinical-stage assets.
Other KPIs
Accelerating. Rose 12% YoY (10% at CER). The 200 basis point expansion in Core Operating Margin (to 34%) signals that management is fully capable of navigating the Farxiga LOE without compromising bottom-line commitments to investors.
Stable. Represents 24% of Total Revenue, completely aligned with management's long-term guidance of maintaining R&D spend in the low-to-mid 20s as a percentage of revenue to feed the post-2030 pipeline.
Guidance
Stable. The company reconfirmed its revenue target. Implied growth is exactly in line with the 6% YoY total revenue growth delivered in Q1 and Q2. This assumes the Oncology outperformance will continue to offset the 15%+ declines in the CVRM portfolio.
Stable. Reconfirmed. Given that Q2 delivered 21% growth and Q1 delivered 5%, the H1 average puts them safely on track to hit the low-teens target, showcasing superior operating leverage.
Stable. Reconfirmed. Q2 delivered a 15% rate (benefitting from internal legal entity changes), providing a slight tailwind to H1 EPS, but expected to normalize back into the guided range for the full year.
Key Questions
Farxiga Base Stabilization
Farxiga revenues dropped 16% globally in Q2. At what point do you expect the U.S. generic impact and China VBP headwinds to fully annualize, and what is the baseline revenue we should model for this franchise going into 2027?
Rare Disease Deceleration
The Rare Disease segment growth slowed to 9% this quarter, primarily driven by a 27% decline in Soliris. Is this faster-than-expected cannibalization the new normal, or can we expect a re-acceleration as pipeline assets like efzimfotase alfa come to market?
China VBP Depth
With China revenues declining 7% this quarter, are we at peak VBP impact, or are there additional legacy assets facing inclusion in the near term that could keep this region in negative territory?